Big Pharma's Pick-Me-Up: A Down Dollar

S&P's Herman Saftlas is upbeat about a brace of drug stocks, while colleague Frank DiLorenzo sees smaller gains for biotechs

Pharmaceutical stocks should hold up well this year as earnings improve, thanks to new-product launches and the weaker dollar, says Herman Saftlas, who follows the industry for Standard & Poor's. Biotech stocks, though, have already had a good run this year and aren't likely to be as strong in the remainder of the year, according to S&P's biotech analyst Frank DiLorenzo.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.